Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced its common stock will be added to the MSCI USA Small Cap Index effective November 30, 2021. This milestone follows the earlier inclusion in the Russell 2000 and Russell 3000 Indexes. The MSCI USA Small Cap Index encompasses 1,851 constituents and represents about 14% of the U.S. equity market's free float-adjusted market cap. CEO Nadav Kidron expressed optimism regarding this inclusion, noting its potential to broaden the company's shareholder base.
Oramed Pharmaceuticals has announced that it has enrolled over 75% of the 675 patients targeted for its Phase 3 study, ORA-D-013-1, evaluating its oral insulin capsule, ORMD-0801, for type 2 diabetes treatment. This study is significant as the first FDA-approved Phase 3 oral insulin trial, testing patients currently on glucose-lowering agents. Topline results are expected in 2022 after a 6-month treatment assessment of glycemic control. Concurrently, a second Phase 3 study commenced enrollment in March, aiming for 450 patients.
MyMD Pharmaceuticals has formed a joint venture with Genomma Lab to develop Oravax's oral COVID-19 vaccine candidate in Mexico. This partnership leverages Genomma's distribution networks in Latin America. Oravax's vaccine aims to be a pioneering oral solution, potentially easier to distribute than traditional injections. The global COVID-19 vaccine market is anticipated to reach $25 billion by 2024, with significant opportunities in Latin America. Oravax has also received regulatory approval to initiate clinical trials in South Africa and is preparing for trials in Israel.
Oramed Pharmaceuticals, through its subsidiary Oravax Medical, has formed a 50/50 joint venture with Genomma Lab to develop and commercialize an oral COVID-19 vaccine in Mexico. The initiative will leverage Genomma Lab's supply chain and market expertise in Latin America. They plan a US$20 million share swap to align interests, with Genomma Lab also committing future investments in Oravax. Oravax's vaccine targets three SARS CoV-2 proteins, potentially offering stronger efficacy against variants. The joint venture aims to expedite emergency approval and address the Latin American vaccine market, estimated at 662 million people.
Oramed Pharmaceuticals (Nasdaq: ORMP) will have CEO Nadav Kidron present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 11:30 am Eastern. The presentation will focus on their innovative oral drug delivery technology and its lead candidate, ORMD-0801, aimed at transforming diabetes treatment as a potential oral insulin capsule. The event can be accessed online for 90 days following the presentation. Visit www.oramed.com for further details.
Oramed Pharmaceuticals has successfully closed a registered direct offering of 2,000,000 shares of common stock at $25 per share, yielding gross proceeds of $50 million. The funds will be utilized for working capital and general corporate purposes. The offering was facilitated by H.C. Wainwright & Co. and follows a previously filed shelf registration statement. Oramed is focused on oral drug delivery systems, particularly its lead candidate, ORMD-0801, which aims to provide a breakthrough oral insulin solution for diabetes treatment.
Oramed Pharmaceuticals, a clinical-stage pharmaceutical company, has announced a registered direct offering of 2,000,000 shares of common stock priced at $25 per share, aiming to raise $50 million in gross proceeds. The offering is expected to close on or about November 5, 2021. The funds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent. This follows a previous shelf registration statement filed on July 15, 2021, which was declared effective on July 26, 2021.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that its subsidiary, Oravax Medical Inc., received clearance from the South African Health Products Regulatory Authority to initiate a Phase 1 clinical trial for its oral COVID-19 vaccine. This vaccine utilizes virus-like particle technology targeting three SARS-CoV-2 proteins, potentially enhancing efficacy against variants. The trial, which aims to simplify vaccine distribution by allowing self-administration, is set to begin shortly, with plans for a Phase 2/3 trial for emergency approval following successful results.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the Cantor Fitzgerald Global Healthcare Conference, occurring virtually from September 27-30, 2021. Kidron's presentation is scheduled for September 30, 2021, at 12:00 P.M. Eastern time. Oramed is focused on developing innovative oral drug delivery systems, notably for diabetes treatment, with their lead candidate ORMD-0801 under pivotal Phase 3 studies.
Oramed Pharmaceuticals (Nasdaq: ORMP) has achieved over 50% patient enrollment in its Phase 2 trial for ORMD-0801, an oral insulin capsule aimed at treating non-alcoholic steatohepatitis (NASH) in Type 2 diabetes patients. The trial will measure key efficacy endpoints like liver fat content and fibrosis after 12 weeks. NASH represents a significant unmet medical need, with no current approved treatments. The global NASH drug market is projected to reach $84 billion by 2029, highlighting the potential for ORMD-0801 to address this issue.